Login to Your Account

Juicier Plum For Suitors

Biogen, Neurimmune Entering Alzheimer's Deal: Up To $360M

By Randall Osborne

Wednesday, November 21, 2007
Amid reports of pre-holiday bidding for Biogen Idec Inc., the firm's potential $380 million deal with the Swiss firm Neurimmune Therapeutics AG for antibodies against Alzheimer's disease signals a business-as-usual approach that could make Biogen that much more tempting to would-be acquirers. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription